A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2023-08-02
AEs
4
Serious
1
Dropout signal
–
Adverse events
severe
serious
assessed
Grade 3 Hypothyroidism — outcome: RECOVERED/RESOLVED; onset 2023-11-21 (study day 106); relationship: not assessed; serious criteria: hospitalization
moderate
assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-01-28 (study day 174); relationship: N
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-03-31 (study day 237); relationship: N
severe
assessed
Grade 3 Vomiting — outcome: RECOVERED/RESOLVED; onset 2024-06-04 (study day 302); relationship: N
Data queries
No data queries.